Midostaurin
From Infogalactic: the planetary knowledge core
(Redirected from PKC412)
180px | |
Ball-and-stick model of the midostaurin molecule | |
Systematic (IUPAC) name | |
---|---|
(9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one
|
|
Clinical data | |
Legal status |
|
Routes of administration |
Oral |
Identifiers | |
CAS Number | 120685-11-2 |
ATC code | None |
PubChem | CID: 9829523 |
IUPHAR/BPS | 5702 |
ChemSpider | 8005258 |
UNII | ID912S5VON ![]() |
ChEMBL | CHEMBL608533 |
Synonyms | 4'-N-benzoylstaurosporine |
Chemical data | |
Formula | C35H30N4O4 |
Molecular mass | 570.637 g/mol |
|
|
|
Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus, and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor, FLT3).[1]
After successful Phase II clinical trials, a Phase III trial for AML has started in 2008. It is testing midostaurin in combination with daunorubicin and cytarabine.[2] In another trial, the substance has proven ineffective in metastatic melanoma.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Clinical trial number NCT00651261 for "Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia" at ClinicalTrials.gov
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Protein kinase inhibitors
- Alkaloids
- Lactams
- Indolocarbazoles
- Antineoplastic and immunomodulating drug stubs